Results 301 to 310 of about 40,773 (330)

Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease. [PDF]

Cardiovasc Diabetol
Li Y, Li D, Lin J, Zhou L, Yang W, Yin X, Xu C, Cao Z, Wang Y.   +8 more
europepmc   +1 more source

Author Correction: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. [PDF]

NPJ Aging
Ikegami Y, Inoue I, Inoue K, Shinoda Y, Iida S, Goto S, Nakano T, Shimada A, Noda M.   +8 more
europepmc   +1 more source

Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta-Analysis of Randomised Controlled Trials. [PDF]

Endocrinol Diabetes Metab
Basit J, Ahmed M, Singh P, Ahsan A, Zulfiqar E, Iqbal J, Fatima M, Upreti P, Hamza M, Alraies MC.   +9 more
europepmc   +1 more source

Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field. [PDF]

Curr Atheroscler Rep
Di Giacomo-Barbagallo F, Andreychuk N, Scicali R, Gonzalez-Lleó A, Piro S, Masana L, Ibarretxe D.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PCSK9 causes inflammation and cGAS/STING pathway activation in diabetic nephropathy

The FASEB Journal, 2023
Our previous research revealed that an increase in PCSK9 is linked to aggravated inflammation in the kidneys of mice affected by a high‐fat diet and streptozotocin (HFD/STZ) or in HGPA‐induced HK‐2 cells.
Zhicai Feng, Xiangyu Liao, Juan Peng, Jingjing Quan, Hao Zhang, Zhijun Huang, B. Yi   +6 more
semanticscholar   +1 more source

Understanding PCSK9 and anti-PCSK9 therapies [PDF]

Journal of Clinical Lipidology, 2015
Inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. To appreciate the efficacy of these agents and interpret research results, it is important to understand the dynamic relationship between PCSK9, low-density ...
openaire   +2 more sources

Targeting PCSK9 for Hypercholesterolemia

Annual Review of Pharmacology and Toxicology, 2014
Dyslipidemias are a predominant risk factor for cardiovascular disease. Biological and genetic research has led to the identification of several genes and proteins that may be pharmacologically targeted to improve lipoprotein profiles and possibly cardiovascular outcomes in patients with dyslipidemia.
G.D. Norata, G. Tibolla, A.L. Catapano
openaire   +4 more sources

Clinical aspects of PCSK9

Atherosclerosis, 2011
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials.
Philippe Costet, Cédric Le May, Bertrand Cariou, Bertrand Cariou   +3 more
openaire   +4 more sources

PCSK9 and diabetes: is there a link?

Drug Discovery Today, 2017
Diabetes mellitus (DM) is associated with an increased risk of cardiovascular disease (CVD). Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as effective low-density lipoprotein cholesterol-lowering compounds. Although the results of available epidemiological, preclinical, and clinical studies suggest a positive ...
Maciej Banach, Evan A. Stein, Matteo Pirro, Amir Abbas Momtazi, Amirhossein Sahebkar, Amirhossein Sahebkar   +5 more
openaire   +4 more sources